Jul. 3 at 8:04 PM
$AKBA Bottom line: Vafseo provides effective oral treatment for anemia in dialysis patients without injections, reduces nursing workload and dialysis unit burden, and in the VOICE trial was associated with fewer hospitalizations than darbepoetin alfa.
list of Vafseo (vadadustat) advantages over injectable ESAs (Epogen, Aranesp, Mircera):
Oral tablet — no injections.
Eliminates injection and needle use.
No nursing time needed to prepare and administer ESA injections.
Less distraction of dialysis nursing staff, allowing to pay attention to patient care.
Reduces workload in dialysis units.
Simplifies anemia management and medication administration.
Decreases the need for ESA storage, preparation, and disposal of needles and syringes used .
Reduced hospitalization compared with darbepoetin alfa in the VOICE trial (approximately 13% lower risk of first hospitalization).
Similar effectiveness in maintaining hemoglobin when used as indicated.
